CFO appointment
Armata Pharmaceuticals, Inc. appoints David House as CFO
Armata Pharmaceuticals, Inc. reported in a Form 8-K filed July 20, 2026 that David House was appointed Chief Financial Officer, effective July 17, 2026.
In the filing's words
On July 17, 2026, the Board of Directors (the “ Board ”) of Armata Pharmaceuticals, Inc. (the “ Company ”) promoted and appointed David House as the Company’s Chief Financial Officer, effective July 17, 2026. Mr. House previously served as the Company’s Senior Vice President, Finance and principal financial officer since August 2024.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Armata Pharmaceuticals, Inc. (ARMP) |
|---|---|
| Event | Appointment |
| Incoming | David House |
| Title in the filing | Chief Financial Officer |
| Effective | July 17, 2026 |
| 8-K filed | July 20, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Senior Vice President, Finance and principal financial officer, Armata Pharmaceuticals, Inc. |
| SEC CIK | 0000921114 |
Armata Pharmaceuticals, Inc. reported this change in a Form 8-K, Item 5.02, filed July 20, 2026. The filing's own words are quoted above.
Same industry, July 2026
4Other moves filed that month at companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
3 months ago· 2026-07-31AppointmentQNCX
Quince Therapeutics, Inc. appoints John Militello as CFO
3 months ago· 2026-07-27TransitionDTIL
Precision BioSciences, Inc. CFO transition: Naresh Tanna to succeed Alex Kelly
3 months ago· 2026-07-23TransitionIMA
ImageneBio, Inc. CFO transition: Yanina Grant-Huerta to succeed Kristin Yarema, Ph.D.
3 months ago· 2026-07-20AppointmentKLRS
Kalaris Therapeutics, Inc. appoints Liisa Bayko as CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about David House? Send a correction with the primary source.